ČESKÁ UROLOGIE / CZECH UROLOGY – 4 / 2020

259 PŘEHLEDOVÝ ČLÁNEK Ces Urol 2020; 24(4): 247–260 8. Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA‑RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies. European Urology 2018; 73(4): 485–487. 9. Rhee H, Thomas P, Shepherd B, et al. Prostate Specific Membrane Antigen Positron Emission Tomogra‑ phy May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. Journal of Urology 2016; 196(4): 1261–1267. 10. Perera M, Papa N, Roberts M, et al. Gallium-68 Prostate‑specific Membrane Antigen Positron Emi‑ ssion Tomography in Advanced Prostate Cancer – Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate‑specific Membrane Antigen‑avid Lesions: A Systematic Review and Meta‑analysis. European Urology 2020; 77(4): 403–417. 11. Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal of Cellular Biochemistry 2004; 91(3): 528–539. 12. Eiber M, Fendler WP, Rowe SP, et al. Prostate‑Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine 2017; 58(Supplement 2): 67S–76S. 13. Afshar‑Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium‑labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging 2013; 40(4): 486–495. 14. Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PRO‑ MISE): Proposed miTNM Classification for the Interpretation of PSMA‑Ligand PET/CT. Journal of Nuclear Medicine 2018; 59(3): 469–478. 15. Afshar‑Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga­ ‑labelled PSMA ligand HBED‑CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42(2): 197–209. 16. Rauscher I, Düwel C, Haller B, et al. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga­ ‑labeled Prostate‑specific Membrane Antigen‑ligand Positron‑emission Tomography/Computed Tomo‑ graphy in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. European Urology 2018; 73(5): 656–661. 17. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18 F]DCFPyL and [68Ga]Ga‑PSMA‑HBED‑CC for PSMA‑PET Imaging in Patients with Relapsed Prostate Cancer. Molecular Imaging and Biology 2015; 17(4): 575–584. 18. De Visschere PJL, Standaert C, Fütterer JJ, et al. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. European Urology Oncology 2019; 2(1): 47–76. 19. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous 68Ga‑PSMA HBED‑CC PET/MRI Improves the Localization of Primary Prostate Cancer. European Urology 2016; 70(5): 829–836. 20. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44(4): 678–688. 21. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of 68Gallium‑PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Journal of Urology 2016; 195(5): 1436–1443. 22. Uprimny C, Kroiss AS, Decristoforo C, et al. 68Ga‑PSMA-11 PET/CT in primary staging of prostate can‑ cer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44(6): 941–949. 23. Stejskal J, Jaskova V, Pavlicko A, et al. Diagnostika karcinomu prostaty pomocí fuzní biopsie. Ces Urol 2018; 22(2): 87–98. 24. Zalesky M, Stejskal J, Minarik I, et al. Porovnání detekce signifikantniho a nesignifikantniho karcinomu pomoci systematicke a cilene fuzní MRI/TRUS biopsie prostaty. Ces Urol 2018; 22(2): 115–121.